Gilead Sciences, Inc (GILD) News & EventsGILDGilead Sciences, Inc

Nurix and Gilead Extend Research Term by Two Years

Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for this program. Under the collaboration agreement, originally established in 2019, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the collaboration, and Nurix retains options for 50/50 profit and loss sharing for development, commercialization, and co-detailing on up to two programs in the United States, subject to certain restrictions. For programs in which Nurix exercises its option, the parties will share U.S. development costs as well as profits and losses 50/50, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments. In connection with this announcement, Nurix will receive a $10M research term extension fee under the amended collaboration agreement. As of May 31, Nurix is eligible to receive up to approximately $1.3B in total payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. Nurix is also eligible to receive mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. The first program licensed by Gilead under this agreement, GS-6791, is a potent, selective, oral IRAK4 degrader which is now in Phase 1 clinical development.

Gilead Expands Lenacapavir Licensing Agreements for HIV Prevention

Gilead Sciences announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis, PrEP. The agreements cover 120 high-incidence countries and will support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial is ongoing. Key Highlights: If approved, once-yearly lenacapavir could provide a full year of HIV prevention with a single annual dose; PURPOSE 365 is an ongoing Phase 3 study evaluating the pharmacokinetics, safety and tolerability of investigational once-yearly intramuscular lenacapavir for HIV prevention; Across the Phase 3 PURPOSE 1 and PURPOSE 2 trials, twice-yearly lenacapavir demonstrated unprecedented efficacy for HIV prevention; Gilead is extending its global access model for twice-yearly lenacapavir for HIV prevention to enable broad; The expanded agreements represent one of the earliest HIV PrEP access planning efforts undertaken during Phase 3 development and build on Gilead's two decades of experience developing global access pathways for HIV medicines